GlassScriptPhysician profile
Metin Bicen
NPI 1568135903
$3,257.17
in general payments reported to CMS, 2019-2025
24 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.33 · 2022: $721 · 2023: $555 · 2024: $1,273 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.25 | 2023-2025 | Qulipta, Ubrelvy |
| Emd Serono, INC. | $391.76 | 2022-2024 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $370.17 | 2022-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $330.06 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $281.69 | 2022-2025 | Rystiggo, Fintepla, Nayzilam |
| Eisai INC. | $181.75 | 2023-2025 | |
| Novo Nordisk INC | $172.93 | 2023-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $168.01 | 2022-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $140.01 | 2022 | |
| Merz Pharmaceuticals, LLC | $61.18 | 2023 | Xeomin |
| Livanova USA, INC. | $47.94 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $44.31 | 2022-2024 | Valtoco |
| Acadia Pharmaceuticals INC | $41.07 | 2023-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $40.36 | 2022 | |
| Microtransponder, INC. | $36.89 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $28.16 | 2024 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $27.04 | 2025 | |
| Biogen, INC. | $25.92 | 2025 | Skyclarys |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $22.33 | 2021 | |
| Lundbeck LLC | $20.13 | 2024 | Vyepti |
| Acorda Therapeutics, INC | $19.19 | 2024 | Inbrija |
| Neurocrine Biosciences, INC. | $17.15 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $15.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Metin Bicen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.